Propranolol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Propranolol: From an Established Beta-Blocker to Distal Myopathy, Tateyama Type
One-Sentence Summary
Propranolol is a beta-blocker that is already marketed in South Africa, but the registration data available do not state its approved indication. The TxGNN model predicts it may be effective for distal myopathy, Tateyama type, a rare inherited muscle disease. No clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration data provided |
| Predicted New Indication | Distal myopathy, Tateyama type |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Propranolol is a non-selective beta-adrenergic blocker, but the Evidence Pack does not document any pathway linking beta-adrenergic blockade to this rare inherited myopathy.
The high score (99.40%) is a knowledge-graph prediction only. It should not be read as evidence of benefit. Distal myopathy, Tateyama type is a structural muscle disease, and there is no known biological reason for a beta-blocker to alter its course. Until a mechanism is proposed and tested, this remains a hypothesis generated by the model.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| L/5.2/192 | Pur-Bloka 10 | Tablet |
| Q/5.2/158 | Sandoz Propranolol HCl 10 | Tablet |
Both products are oral tablets. The registration data provided do not include approved indication text or manufacturer names.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature (L5) and no documented mechanistic link. The SAHPRA safety information and the mechanism of action are also missing, so the candidate cannot advance to safety screening.
To proceed, the following is needed:
- The SAHPRA package insert (warnings and contraindications), which is currently a blocking gap
- Mechanism of action data from DrugBank
- A biologically plausible mechanism connecting beta-blockade to this myopathy, plus any preclinical or clinical evidence
- Route and dosing compatibility assessment
Other predicted indications in this Evidence Pack
The top-ranked prediction has the weakest evidence. Several lower-ranked predictions have more support and may be better first candidates for review.
| Predicted Indication | TxGNN Score | Evidence Level (as assigned in pack) | Recommendation | Key Caveat |
|---|---|---|---|---|
| Cardiomyopathy | 99.12% | L2 | Proceed with Guardrails | Direct evidence is limited to older, small hypertrophic cardiomyopathy studies, including one 1973 double-blind trial. The three listed trials are deprescribing or traumatic brain injury studies and do not test propranolol as a cardiomyopathy therapy. Caution is needed in dilated or decompensated disease. |
| Breast capillary hemangioma | 98.90% | L3 | Research Question | Support is indirect: a large real-world study of propranolol (Hemangiol) in infantile hemangioma. There is no breast-specific data. |
| Cirrhotic cardiomyopathy | 99.12% | L4 | Research Question | One study suggests propranolol shortens prolonged QT in cirrhosis, but others show impaired circulatory and renal function in some patients. |
| Intramuscular hemangioma | 98.97% | L4 | Research Question | Propranolol is established for infantile hemangioma (including an RCT of propranolol gel), but evidence for intramuscular hemangioma is extrapolated. |
The remaining predictions (congenital myopathy with excess of thin filaments, athletic hypertrophic cardiomyopathy, chondroma, Maffucci syndrome, breast epithelioid hemangioma) have no direct evidence or only keyword-matched literature, and are on Hold.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.